N.E. Verstegen

Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer

Frank J. Lagerwaard, N.E. Verstegen, Cornelis J.A. Haasbeek et al. · International Journal of Radiation Oncology*Biology*Physics · 2011 · 339 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis

N.E. Verstegen, J. Wolter Oosterhuis, David A. Palma et al. · Annals of Oncology · 2013 · 274 citations · Full text

Medicine, Oncology, Surgery +17

Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: Comparison with a contemporaneous cohort with pathologically proven disease

N.E. Verstegen, Frank J. Lagerwaard, Cornelis J.A. Haasbeek et al. · Radiotherapy and Oncology · 2011 · 142 citations

Medicine, Oncology, Radiation Oncology +9

Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: Results from propensity score analysis

Sahar Mokhles, N.E. Verstegen, Alex P.W.M. Maat et al. · Lung Cancer · 2015 · 73 citations

Medicine, Oncology, Surgery +13

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy

N.E. Verstegen, Frank J. Lagerwaard, Sayed M.S. Hashemi et al. · Journal of Thoracic Oncology · 2015 · 58 citations · Full text

Medicine, Oncology, Surgery +15